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Abstract
Background: Pancreatic stone protein (PSP) has been identified as a promising sepsis marker in adults, children
and neonates. However, data on population-based reference values are lacking. This study aimed to establish
age-specific reference values for PSP.
Methods: PSP was determined using a specific ELISA. PSP serum concentrations were determined in 372 healthy
subjects including 217 neonates, 94 infants and children up to 16 years, and 61 adults. The adjacent categories
method was used to determine which age categories had significantly different PSP concentrations.
Results: PSP circulating levels were not gender-dependent and ranged from 1.0 to 99.4 ng/ml with a median of
9.2 ng/ml. PSP increased significantly between the age categories, from a median of 2.6 ng/ml in very preterm
newborns, to 6.3 ng/ml in term newborns, to 16.1 ng/ml in older children (p < 0.001). PSP levels were higher on
postnatal day three compared to levels measured immediately post delivery (p < 0.001). Paired umbilical artery and
umbilical vein samples were strongly correlated (p < 0.001). Simultaneously obtained capillary heel-prick versus
venous samples showed a good level of agreement for PSP (Rho 0.89, bias 19 %).
Conclusions: This study provides age-specific normal values that may be used to define cut-offs for future trials on
PSP. We demonstrate an age-dependent increase of PSP from birth to childhood.
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Background
In recent years, a number of biomarkers have been in-
vestigated as candidates to improve the ability to diag-
nose infection and sepsis in newborns, children and
adults [1–6]. A limitation of several recently proposed
infection markers is the lack of larger cohorts providing
populational serum concentration measurements in
order to establish normal reference values. This is im-
portant because the performance of most biomarkers is
context-sensitive and in some cases age-specific. For
example, C-reactive protein is increased after surgical
interventions [7], which reduces its specificity to diag-
nose infections in postoperative patients. Procalcitonin
(PCT) is physiologically elevated during the first 48 h of
life, which has to be taken into account when defining
optimal cutoffs for the diagnosis of neonatal early-onset
sepsis [6].
Pancreatic stone protein (PSP) has recently emerged
as a promising marker of sepsis [8, 9]. PSP has so far
been studied predominantly in adults, and was shown to
predict multi-organ failure and mortality in patients with
ventilator-associated pneumonia and post-traumatic sep-
sis [8, 9]. A study using a bioscore combinding PSP with
procalcitonin (PCT) significantly improved the ability to
diagnose neonatal early-onset sepsis, with a negative
predictive value of 100 % if both PSP and PCT were
negative [10]. These data suggest that PSP is a promising
candidate for further studies assessing performance and
use in clinical practice. To date, however, no reference
values are available for PSP. While its main physiological
role is poorly understood, PSP may act by promoting
cellular proliferative responses in the pancreas and was
shown to activate polymorphonuclear cells [9]. Animal
studies have shown induction of PSP expression in
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subsets of intestinal and gastric cells by stress conditions
in the absence of direct pancreatic inflammation [11].
The present study aimed to determine circulating PSP
serum levels in healthy individuals from birth to adult-
hood in order to provide reference values for clinical use
and future studies.
Methods
Study subjects
Subjects for this study were recruited through three
different studies conducted between July 1st 2009 and
December 31st 2012. Study subjects were eligible if they
did not present with any infection or major disease at
time of sampling, and if subsequent investigation for
infection resulted negative. The study was submitted to
and approved by the institutional ethics committees at
each of the involved hospitals (Cantonal Ethics Commit-
tees of the Canton of Berne, Canton of Zurich and
Canton of Lucerne, and Bicantonal Ethics Committee of
Basel, Switzerland). Written consent from the parents of
pediatric participants, and from adult study participants
was obtained.
104 patients included in this study were enrolled
through the prospective, randomized-controlled multi-
centre Neonatal Procalcitonin Intervention Study (Neo-
PInS, see http://www.clinicaltrials.gov, trial number
NCT00854932) [12], in three Swiss neonatal intensive
care units (Department of Neonatology, University
Children’s Hospital Bern and Children’s Hospital Lucerne;
Department of Pediatrics, Cantonal Hospital Winterthur,
Switzerland). Children were included in the present study
only if they were admitted within the first 72 h of life to
the Neonatal Intensive Care Unit for suspicion of early-
onset sepsis that was subsequently ruled out. Infection
was ruled out using all of the following criteria: 1.
Negative cultures, 2. Normal infection markers, 3. No
signs of systemic inflammatory response syndrome
(SIRS). Newborns with complex congenital malforma-
tions, chromosomal aberrations, and congenital heart
disease and those who died within the first week after
admission were excluded.
Umbilical cord blood samples were obtained in 113
patients. Umbilical cord samples paired with postnatal
samples were obtained prospectively at the University
Hospital of Zurich, Switzerland, between August 2011
and April 2012 in preterm and term newborns in the
absence of major neonatal disease, infections or comor-
bidities [13]. Umbilical cord blood was collected from
the umbilical artery (UA) and the umbilical vein (UV)
after delivery of the placenta. Peripheral blood was then
collected on day of life three in 22 infants.
Venous samples in the pediatric age groups were
recruited through a prospective study in 94 children
(aged between >1 month and 16 years) admitted for
elective surgery at the Department of Pediatrics, Univer-
sity of Lausanne, Switzerland, between April 26, 2012, and
December 20, 2012. Infants and children with acute or
chronic infection, severe underlying disease or chromo-
somal abnormality were excluded from the study.
Venous samples from adults were recruited through
healthy adult volunteers (N = 61).
Blood sampling
In each patient, 100 μl of blood was sampled. Samples
were centrifuged directly after sampling for 6 min at
3000 G, the serum was then frozen within less than 4 h
in sterile tubes at −80 °C until measurement. Venous
blood was taken by venipuncture from a peripheral vein.
PSP was measured in simultaneous samples obtained
in the umbilical artery and the umbilical vein in 21
infants. Cord blood was collected immediately after
delivery of the child from the umbilical vein at the
placental side of the cord.
In 20 newborns, 100 μl of capillary and 100 μl of venous
blood were sampled simultaneously [14]. Venous blood
was taken by venipuncture from a peripheral vein using
IV catheters (Insyte-N™ 24G, Becton Dickinson AB,
Helsingborg, Sweden). Capillary blood was taken by heel
prick with an automated lancet (Tenderfoot preemie®,
ITC, Edison, New Jersey, USA). The thereby collected
tubes (S-Monovette®, and Microvette 100®, Sarstedt AG &
Co., Nümbrecht, Germany) were centrifuged directly after
sampling for 6 min at 3000 G, the serum was then imme-
diately frozen in sterile tubes at −80 °C.
Pancreatic stone protein (PSP) measurements
PSP was analyzed using a specific ELISA as previously
described [9]. In brief, patient serum was incubated with
guinea pig anti-human PSP/reg antibody precoated
plates. Rabbit anti-human PSP/reg was added and subse-
quently detected by phosphatase-conjugated anti-rabbit
IgG. The detection limit was 0.1 ng/mL and the inter-
plate variance was <10 %.
Statistical methods
In the figures displaying PSP serum concentrations vs.
age, logarithmized scales were used. To cover the wide
age range from preterm and term neonates over children
to adults, AgeGraphics calculated in years from week 0
gestational age (wGA) was used here. The specific calcu-
lations were AgeGraphics = wGA/52 for neonates, and
AgeGraphics = age in years + 40/52 for children and
adults. The age-dependent estimate of the mean and its
95 % confidence interval were calculated by fourth de-
gree linear regression. The adjacent categories method,
applying the Wilcoxon– Mann–Whitney test, was used
to determine which age categories had significantly dif-
ferent PSP concentrations as described [15]. It started
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with 12 categories defined by 11 age limits set at <32
and <37 (preterm neonates), <40, and <42 wGA (term
neonates), <1 year (infants), <4, <8, <12, and <16 years
(children and adolescents), and <30 and <50 years
(adults). Then, adjacent age categories with the least sig-
nificant differences were combined step by step until
concentrations were significantly different between the
resulting combined age categories. For these categories,
the minimum, the 10th percentile (P10), P25, the me-
dian (P50), P75, P90, the maximum, and the number
and proportion of results ≤ P10 in adults and ≥ P90 in
adults were calculated.
Bland-Altman plots were constructed, and the mean
bias and the 95 % limits of agreement were calculated
based on logarithmized concentrations.
Two-sided tests were used throughout, and p-values
<0.05 were considered statistically significant. The soft-
ware used was R 3.0.2 (R Foundation for Statistical
Computing, Vienna, Austria), SPSS 18.0 (SPSS Inc.,
Chicago, Illinois, USA), and Prism 5.0c (GraphPad
Software, La Jolla, California, USA).
Results
PSP serum concentrations were determined in 372
healthy subjects including 217 neonates, 94 infants and
children up to 16 years; and 61 adults. Neonatal samples
included cord blood samples from 113 infants born
between 27.6 and 41.9 weeks gestational age (median
gestational age 39 weeks, IQR 35.1 to 40.3 weeks), and
postnatal samples in 104 newborns born between 34.0
and 42.0 weeks (median gestational age 39 weeks, IQR
35.5 to 40.2 weeks). Control samples in adults were
received from volunteers of a Caucasian population with
a median age of 45 years (19–82). There was no gender
difference in the PSP values in adults.
PSP ranged from 1.0 to 99.4 ng/ml with a median of
9.2 ng/ml. PSP was non-normally distributed (Shapiro-
Wilks test statistic, W = 0.6793; p < 0.001), whereas
logarithmically transformed PSP concentrations were ap-
proximately normally distributed (W = 0.989; p = 0.007;
Fig. 1). Figure 2 shows the bell-shaped distribution of
PSP from birth to adulthood. PSP increased significantly
between the age categories, from a median of 2.6 ng/ml
in very preterm newborn, to 4.5 ng/ml in preterm new-
born, to 6.3 ng/ml in term newborn before 40 weeks
gestational age, to 8.4 ng/ml in term newborn after 40
weeks gestational age and infants, and to 16.1 ng/ml in
older children. Values in adults were significantly lower
than in children with a median of 10.8 ng/ml (p < 0.001),
but still higher than in newborns (Table 1). PSP serum
levels in cord blood were higher in infants born with peri-
natal acidosis (Spearman’s Rho −0.25, p < 0.001). PSP
levels were not significantly different between male and fe-
male study subjects (Mann–Whitney Z −1.68, p = 0.094).
Delivery mode (cesarean versus vaginal) was not associ-
ated with PSP levels (Z −0.059, p = 0.95).
In order to assess changes of PSP during the first days
of life, PSP was measured sequentially in cord blood and
on day 3 of life in 22 patients. Cord blood and postnatal
samples were positively correlated (Rho 0.73, p < 0.001).
PSP showed a significant postnatal increase (median
14.1 versus 5.4 ng/ml, p < 0.001), see Fig. 3.
We tested whether the site of blood collection had an
influence by comparing the values from umbilical vein
versus umbilical artery, and capillary heel prick versus
venous blood. Paired umbilical artery and umbilical vein
samples were strongly correlated (N = 21, Spearman’s
Rho 0.96, p < 0.001). Correspondingly, there was not a
relevant difference between umbilical vein versus umbil-
ical arterial PSP concentrations (p = 0.50).
PSP concentrations were then compared between sim-
ultaneously obtained capillary heel-prick versus venous
samples with a good level of agreement (n = 20, Rho
0.89, bias 19 %, Fig. 4a and b). The limits of agreement
between capillary and venous samples for PSP were
comparable to the calculated limits of agreement based
on the coefficients of variation of the assay.
Discussion
We report on age-specific serum concentrations in PSP
in healthy individuals. The results indicate that PSP
shows a relevant age-dependent variation, with lowest
values observed in premature newborns, followed by a
rise until childhood and adolescence. We observed a
Fig. 1 Histogram of logarithmically transformed Pancreatic Stone
Protein (PSP) serum concentrations in 372 healthy subjects (dark
grey, 217 neonates; light grey, 94 infants and children up to 16
years; white, 61 adults above 16 years)
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slight decrease of PSP serum concentrations in adults in
comparison to children and adolescents. We observed a
significant increase of PSP with increasing gestational
age, and a more than twofold postnatal rise.
PSP has predominantly been studied in critically ill
adults, with highest levels found in patients with sepsis
and multi-organ failure [1, 8, 9]. In recent ICU based
studies, high PSP levels predicted mortality in septic
adults, whereas established infection markers such as
CRP or PCT were increased in presence of infections,
but did not allow to stratify for sepsis mortality risk
[16, 17]. In a study on critically ill children, PSP
levels were significantly higher in patients with multi-
organ dysfunction syndrome, and patients who died
tended to have higher PSP levels accordingly [18].
Similarly, increased PSP levels were observed in new-
borns with early-onset sepsis [10]. The performance
of PSP was comparable or superior to other markers
such as CRP, PCT or soluble human triggering recep-
tor expressed on myeloid cells-1 (sTREM-1), suggest-
ing PSP is independently increased in presence of
infections. In addition, studies performed in ICUs in-
dicate that significant PSP increase occurs in presence
of significant stress and multi-organ failure [1, 8, 9].
Previous publications investigating PSP in sepsis and
shock defined optimal cutoff thresholds using receiver-
operating characteristics curve analyses based on the
respective study cohorts. Notably, these resulted in dif-
ferent cutoffs for PSP, which were mostly higher than
the 90th centile for PSP in the populational reference pa-
tients in our cohort. For example, in newborns with
early-onset sepsis, a PSP cutoff of 9 ng/ml discriminated
best from non-infected infants [10]. In adult patients
with chronic obstructive pulmonary disease, PSP cutoff
values of 33.9 ng/mL combined with the presence of
discolored sputum had a specificity of 97 % to identify
patients with pathogenic bacteria on sputum culture
[19], and predicted exacerbations. PSP >130 ng/ml pre-
dicted mortality in adults with peritonitis [17]. Of note,
adult studies in patients with sepsis reported serum con-
centrations as high as >1000 ng/ml [17]. In view of the
considerable variability in cutoffs used by previous stud-
ies, the present study fills an important gap by providing
reference ranges for future studies [20]. In practice, dif-
ferent thresholds for PSP may need to be applied in
newborns compared to older age groups.
Of note, the inter-individual variability of PSP was
highest in the umbilical cord values, with a range from 1
Fig. 2 Serum concentration of Pancreatic Stone Protein (PSP) vs. age in a) 372 healthy subjects, and b) 217 healthy neonates. The solid line indicates
the mean predicted by linear regression with its 95 % confidence interval. The dotted lines indicate limits between age categories with significantly
different serum concentration
Table 1 Serum concentration of pancreatic stone protein in ng/mL
Age category N Minimum P10 P25 Median P75 P90 Maximum N (%) ≤ P10adult N (%) ≥ P90adult
<32 wGA 15 1.1 1.4 2.0 2.6 4.3 6.8 10.1 14 (93 %) 0 (0 %)
32 wGA to 36 wGA 62 1.0 2.2 3.5 4.5 8.4 12.1 99.4 45 (73 %) 4 (6 %)
37 wGA to 39 wGA 71 1.5 3.0 4.0 6.3 10.2 16.5 68.0 37 (52 %) 11 (15 %)
40 wGA to <1 year 89 2.1 3.7 5.9 8.4 12.5 16.4 74.4 37 (42 %) 11 (12 %)
1 year to <16 years 74 6.3 10.3 12.0 16.1 20.2 25.0 43.0 4 (5 %) 45 (61 %)
Adults 61 4.0 7.6 9.0 10.8 12.5 14.5 18.3 7 (11 %) 7 (11 %)
P Percentile, wGA Weeks gestational age, yr year
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to 99 ng/ml, and PSP was increased in infants with peri-
natal acidosis. These findings may suggest that the stress
response associated with birth can increase PSP.
Interestingly, a large number of serum proteins show a
physiologic increase with gestational age followed by
rapid postnatal increase [21]. The precise mechanisms
are unclear, and likely relate to a transient physiological
systemic inflammatory response due to the microbio-
logical colonization of skin and mucosal surfaces, includ-
ing gut exposure to microbiota [22].
Strengths of the present study include the large sample
size capturing a wide range of age span from extremely
preterm infants to older adults, and the restriction of
samples to individuals in the absence of with disease or
infection. The good agreement between capillary and
venous PSP samples observed suggests that capillary
sampling for PSP is accurate, which may facilitate
further studies on PSP in neonates and young children.
Blood sampling in neonates and children may represent
considerable challenge due to practical issues with access
difficulty, patient pain, and parental anxiety [14, 23].
Capillary sampling involving adequate skin warming is
often used as a rapid and safe alternative in neonates
and young children.
This study has a number of limitations. For ethical
reasons, it was not feasible to obtain sequential PSP
samples over a prolonged period of time in newborns
and children. A subset of PSP samples were obtained in
neonates enrolled in a sepsis marker study, where infec-
tion had been ruled out. Due to issues with sampling in
the pediatric age group, PSP was measured in otherwise
healthy newborns and in children undergoing general
anaesthesia. As sampling occurred upon induction of
anaesthetics for minor and elective procedures, it is un-
likely that acute-phase response due to the procedure
relevantly influenced PSP values in this group. The neo-
natal group was carefully selected to exclude patients
with infection or major disease.
Conclusions
PSP levels change significantly with age with lowest
levels seen in extremely preterm babies, and highest
levels observed in children. We observed a significant
post-natal rise. The present study provides age-specific
serum concentrations of PSP in healthy individuals
which may be used as a reference data to establish opti-
mal cut-offs in future studies on PSP.
Key messages
 Pancreatic Stone Protein (PSP) has recently emerged
as a promising marker of sepsis, and sepsis mortality
in adult and neonatal intensive care studies.
Fig. 3 Postnatal increase of Pancreatic Stone Protein (PSP). Paired PSP
determinations in cord blood (birth) and on the third day of life (day 3)
are shown (n = 22). The p-value of the Wilcoxon signed rank test is given
Fig. 4 Comparison of capillary and venous Pancreatic Stone Protein (PSP) concentrations. a Scatter plot comparing capillary and venous PSP
concentrations. The bisecting line is shown (straight line, indicating 100 % agreement). The correlation coefficient of the Spearman’s rank test
(Rho) is given. b Bland-Altman plot showing the difference between logarithmically transformed capillary to venous Pancreatic Stone Protein
(PSP) concentration plotted against the average of capillary and venous concentration. Bias (mean difference, dotted line) and 95 %-limits of
agreement (dashed lines) are shown. The units shown indicate logarithms (base 10) of PSP concentrations (ng/ml)
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 The present study provides age-specific reference
values for PSP that confirm that PSP concentrations
vary with patient age.
 The populational values provided in this study may
serve as references for future studies to define
optimal cut-off thresholds.
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